Tag: AVXLD

Buzz

The Buzz only Get’s Bigger as $AVXL is now on Nasdaq and the Price Closes in on $15!

[cmwizard menu=avxlmenu title=”Full Coverage AVXL”/] Yes, we’ve been all over Anavex Life Sciences Corp (NASDAQ: AVXL, AVXLD recently) for MONTHS.  Since we started, things have gone from very good to GREAT. Things have gone from Over the Counter to Nasdaq. We have a lot of happy members… but forget about us!  Let’s get the real buzz out there as this one tries to conquer and finally go above $15 forever. Didn’t quite make it today. At least we got rid of the D and can enjoy four letter trading again! The Buzz:   Churbz thinks the best thing to do is

Buzz

Buzz on $AVXL $AVXLD – Is StockGuru Behind This Momentum? Find Out Here! #ANAVEX

[cmwizard menu=avxlmenu title=”Full Coverage AVXL”/] I will admit this one post is pure click bait. I keep getting asked this question: “Are you being paid to promote Anavex Life Sciences Corp.  (Nasdaq!: AVXL / AVXLD)?” Here’s an answer I put on Twitter answering “StockMarketNietzsche”  /aka/ ‏@Investor4201: As you can see I am not and never have been paid by anyone to promote or publish on AVXL. It has generated a ton of hits. Likely there are ads on my site that were clicked during the 5000 plus visits, but that would never count as compensation from AVXL.    Second question:

Buzz

Is $AVXL $AVXLD Moving Back Up Above $10? #Anavex Life Sciences Corp.

[cmwizard menu=avxlmenu title=”Full Coverage AVXL”/] This was a huge week for Anavex Life Sciences Corp (OTCQB: AVXL, AVXLD).  There is so much happening as we enter the weekend, I know this is one of the most talked about stocks around.  It is also one of the most moderated stocks around!  Wow, you will see that below. Don’t take that as a negative that I show the deletes. Really, I believe in open discussion, not silencing the bashers!  That’s on Ihub, but first let’s sample the Twitterverse on AVXLD (Can’t wait to get back to just calling it AVXL!). The Buzz… Joseph

Buzz

Let’s Just Face it: The REAL Buzz is on $AVXLD $AVXL – Anavex Life Sciences Corp.

[cmwizard menu=avxlmenu title=”Full Coverage AVXL”/] Look at that chart: That’s a six month chart on AVXL / aka / AVXLD /  Anavex Life Sciences Corp. That really says it all.  The dollar volume here is HUGE. Absolutely huge. Today alone we will cross $20 million! Wow.  Like everyone you see, we take some credit. Of course unlike the others, we write posts about just a few stocks and are pleased we brought you this one early. Back when it was in that May / June range! (Look it up if you don’t believe us.) Okay – Everybody’s talking about this

Buzz

As $AVXL gets its D following Reverse $AVXLD – The Buzz is Bigger than Ever

[cmwizard menu=avxlmenu title=”Full Coverage AVXL”/] Of course the D on the AVXLD will only be there for a total of twenty days, this following the reverse split. There is a huge buzz right now for Anavex Life Sciences Corp. (OTCQB: AVXL – aka – AVXLD).  We all know that reverse splits are supposed to be the worst thing a stock can do.  Guess what? SO FAR… AVXL has shown us otherwise!  This is RARE!   Let’s look at some of that buzz now:  Bruce includes us in his favs, although I don’t agree on the HIMX! @bsbct $HIMX $AVXL !!! —

Biotech

Lot’s of Buzz coming from $CTIX – Cellceutix Corp.

Are you watching Cellceutix Corp. (OTC: CTIX)? We’re hearing more about it. We see a lot of activity on Twitter and Ihub about the stocks. Alan C sees wash trades:   AlanC: $CTIX Cellceutix Corporation: Lots of wash trades yesterday used to simulate http://t.co/bDb1Exu6od — iHangout (@iHangout) October 7, 2015 The P/E Ration – but I don’t see it’s really valid here. But… This post does:  CTIX Cellceutix Corp. P/E Ratio http://t.co/B7utZqHRPE $CTIX $RGBP $XLP $AVXL #CTIX #investing #share — jim50 (@Jim5011) October 7, 2015 The Bid from a forum visitor:  CTIX Cellceutix Corp. Bid http://t.co/O7N1vNzGeA $CTIX $BLUE $CTLE $USO

CORRECTING and REPLACING — Anavex Prepares for Uplisting to NASDAQ, Announces Reverse Stock Split

NEW YORK, Oct. 06, 2015 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain, and various types of cancer, today announced that it is finalizing an application to uplist trading of its common stock to the NASDAQ Capital Market.  To meet the conditions of a NASDAQ listing, the Company announces a one-for-four (1-for-4) reverse stock split of its authorized, issued and outstanding common shares.  The Company’s common stock will begin trading on a post-split basis at the opening of trading

Anavex Prepares for Uplisting to NASDAQ, Announces Reverse Stock Split

NEW YORK, Oct. 06, 2015 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain, and various types of cancer, today announced that it is finalizing an application to uplist trading of its common stock to the NASDAQ Capital Market.  To meet the conditions of a NASDAQ listing, the Company announces a one-for-four (1-for-4) reverse stock split of its authorized, issued and outstanding common shares.  The Company’s common stock will begin trading on a post-split basis at the opening of trading

Buzz

Most Talked About: AVXL – Up 18.44% Today

[cmwizard menu=avxlmenu title=”Full Coverage AVXL”/] A stock that has been moving up and up lately is Anavex Life Sciences Corp. (OTCQX: AVXL). Shares closed up today 18.44% on very strong volume.  Here is some of what we heard on Twitter Today:    $AVXL Up 0.50 since Thursday entry. This one is almost too easy. Writing was on the wall. We’ll see a 3+ handle post data. Mark it! — Scott Hansen (@peteharmisan) October 5, 2015 We heard this from Matt Duffield on Twitter:  @Duffield84 Just took two months but $AVXL and $AQXP market caps are nearly equal now. — Matt Duffield

Anavex Completes Patient Enrollment for Phase 2a Alzheimer’s Trial Ahead of Schedule

NEW YORK, Sept. 28, 2015 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain, and various types of cancer, today announced that patient enrollment for the Phase 2a clinical trial of ANAVEX 2-73 has been completed ahead of schedule.  With the Phase 2a trial now fully enrolled, Anavex expects to release topline data for PART A before the end of the year. “There has been significant interest in our Phase 2a Alzheimer’s trial and full enrollment is an important

Anavex to Present at 2015 Ladenburg Thalmann Healthcare Conference

NEW YORK, Sept. 23, 2015 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain, and various types of cancer, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer, will present at the Ladenburg Thalmann 2015 Healthcare Conference on Tuesday, September 29, 2015 at 4 p.m. ET in Track 1.  The conference will be held at the Sofitel Hotel in New York City. Management plans to be available for one-on-one meetings with members of the investment community

LogMeIn's IoT Platform, Xively, Takes Top Honors at 2015 MassTLC Technology Leadership Awards

BOSTON, Sept. 22, 2015 (GLOBE NEWSWIRE) — LogMeIn Inc.’s (NASDAQ:LOGM) Internet of Things (IoT) platform, Xively, was named the IoT Innovative Technology of the Year winner by the Massachusetts Technology Leadership Council (MassTLC) during the 2015 Technology Leadership Awards. Xively offers management capabilities that help companies securely capture, analyze and manage data, while providing the foundation for any company looking to build a connected product business. The MassTLC selection of Xively comes fresh on the heels of the Salesforce Dreamforce conference in San Francisco where Xively was named as a Salesforce IoT Cloud Partner and showcased six customer implementations of

Anavex Appoints International Alzheimer’s Expert to Scientific Advisory Board

NEW YORK, Sept. 21, 2015 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain, and various types of cancer, today announced the appointment of Harald Hampel, MD, MA, PhD, MSc, to the Company’s Scientific Advisory Board.  An internationally recognized expert on Alzheimer’s and related neurodegenerative diseases, Dr. Hampel is Professor and AXA Research Fund Chair at Sorbonne Universities’ Pierre and Marie Curie University (UPMC) in Paris, the leading university in science, technology and medicine in France.  The AXA-UPMC Chair

Mice Model Market expected to reach USD 1.75 Billion by 2023: Transparency Market Research

Albany – NY, Sept. 9, 2015 (GLOBE NEWSWIRE) — According to a new market report published by Transparency Market Research “Mice Model Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 – 2023“, the global mice model market was valued at USD 1.01 billion in 2013 and is anticipated to expand at a CAGR of 6.4% from 2015 to 2023 to reach USD 1.75 billion by 2023. Mice have been one of the most important research tools for basic and applied research in biomedical sciences and continues to grow at a rapid rate. Besides providing precise correlation

OraSure Technologies Announces 2016 Annual Meeting Date

BETHLEHEM, Pa., Aug. 28, 2015 (GLOBE NEWSWIRE) — OraSure Technologies, Inc. (NASDAQ:OSUR) today announced that its 2016 Annual Meeting of Stockholders is scheduled to be held on Tuesday, May 17, 2016. Further details regarding the meeting will be provided at a later date. About OraSure Technologies OraSure Technologies is a leader in the development, manufacture and distribution of point-of-care diagnostic and collection devices and other technologies designed to detect or diagnose critical medical conditions. Its first-to-market, innovative products include rapid tests for the detection of antibodies to HIV and HCV on the OraQuick® platform, oral fluid sample collection, stabilization and

Blog

Patent Announcement Spikes Volume in Anavex Life Sciences (AVXL)

We’ve all seen how Anavex Life Sciences (OTCQX: AVXL) has moved from the upper 40 cent range to as high as $1.61 in recent days. Volume has been quite strong. Yesterday’s news continued to move the volume, with the price moving wildly between $0.98 and $1.34, finally settling at the close from $1.28. Today we’ve seen a high of $1.34, and it is trading at $1.27 as of publication.  gyrations in the market are always expected with such news.    RECENT NEWS:  Aug 12, 2015 Anavex Receives Notice of Allowance for U.S. Patent Application Related to ANAVEX 2-73 Press Release Aug 10,

Blog

Profile Stock – Anavex Life Sciences Corp. (AVXL) Up 12.26% Intraday

Profile Stock – Anavex Life Sciences Corp. (AVXL) closes up 2.2%. Shares for AVXL were up as much as 12.26% intraday and showed significant upward momentum.  Volume is up 159.4%.     Latest News for AVXL:  Anavex Presents Positive Initial Phase 2a Study Data With ANAVEX 2-73 Showing Early Evidence of Improving Cognition in Patients With Alzheimer’s Disease at AAIC 2015 NEW YORK, July 22, 2015 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX:AVXL) today announced initial positive cognitive data for ANAVEX 2-73, the Company’s lead investigational oral treatment for Alzheimer’s targeting sigma-1 and muscarinic receptors, which is believed